Section 01
What it's used for
Cognitive improvement in patients
Noopept's main approved use. In clinical studies of patients with organic cognitive disorders, it improved attention, memory, both forming and recalling memories, and information processing, with effects appearing within days.
▸Clinical wording
Noopept's primary approved and researched application. Clinical studies in patients with organic cognitive disorders show improvements in attention, memory (both encoding and retrieval), and information processing. Effects are observed within days of starting treatment, with continued improvement over weeks.
Cell study plus a patient trial
In a lab cell-culture model, Noopept reduced toxicity from amyloid-beta and cell death, evidence limited to that one cell model. In patients with mild cognitive impairment, trials comparing it with piracetam reported improvement.
▸Clinical wording
In a PC12 cell-culture model, Noopept has been shown to reduce amyloid-beta(25-35) toxicity, tau hyperphosphorylation, and apoptosis, but this evidence is limited to that cellular model rather than "Alzheimer's disease models" broadly. Clinical studies comparing Noopept with piracetam in patients with mild cognitive impairment report cognitive improvement. No published data support claims that Noopept enhances hippocampal long-term potentiation or spatial memory in aged or cognitively impaired animals.
Brain injury recovery: unstudied
Vendor and community material claims Noopept speeds cognitive recovery after brain injury. But no published study, in cells, animals, or people, has actually tested Noopept for traumatic brain injury or its effects.
▸Clinical wording
Noopept is promoted in vendor and community material as a way to speed cognitive recovery after traumatic brain injury, supposedly through neurotrophic support, reduced inflammation, and enhanced neuroplasticity. No published study, preclinical or clinical, was found testing Noopept in traumatic brain injury, including its effects on spatial learning or brain lesion volume after trauma. This direction currently has no support in the peer-reviewed literature.
Anxiety relief: not clinically tested
Vendor and community material describes Noopept as easing anxiety alongside its cognitive effects. A 2002 review mentions a possible anxiety-reducing action, but only as a brief remark, not a trial or clinical study.
▸Clinical wording
Noopept is often described in vendor and community material as having anxiolytic effects alongside its cognitive benefits, particularly for patients with anxiety and comorbid cognitive impairment. A 2002 pharmacological review mentions a possible "additional selective anxiolytic action" of Noopept, but this is a brief mechanistic remark, not a dedicated clinical trial. No published clinical study was found testing Noopept as an anxiolytic in patients with cognitive impairment.
Stroke protection in animal models
In animal models of stroke, Noopept reduced the size of the damaged brain area and improved functional recovery, working through antioxidant, anti-inflammatory, and nerve-supporting effects. This is preclinical evidence.
▸Clinical wording
Preclinical data demonstrates Noopept reduces infarct volume and improves functional outcomes in stroke models through antioxidant, anti-inflammatory, and neurotrophic mechanisms.
Section 02
Mechanism of Action
More growth factors for brain cells
- Noopept increases production of two nerve growth factors in the hippocampus and the cortex.
- One of them (BDNF) supports synaptic flexibility, branching of nerve cells and memory consolidation.
- The other (NGF) supports the survival and function of nerve cells that use acetylcholine.
- This pair of growth factors is described as the basis of both immediate and longer-lasting effects.
▸Clinical wording
Neurotrophin Upregulation (Primary Mechanism)
Noopept significantly increases expression of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in hippocampus and cortex. BDNF promotes synaptic plasticity, dendritic branching, and memory consolidation through TrkB receptor activation. NGF supports cholinergic neuron survival and function through TrkA receptor signaling. This dual neurotrophic mechanism underlies both acute cognitive enhancement and long-term neuroprotective effects.
Strengthening the main learning signal
- Noopept boosts signalling at receptors for glutamate, the brain's main excitatory messenger in learning and memory.
- It acts as a positive modulator, raising receptor sensitivity without causing damaging overexcitation.
- Stronger glutamate signalling reinforces long-term potentiation, the synaptic change that underlies memory formation.
▸Clinical wording
Glutamatergic Modulation
Noopept enhances AMPA and NMDA glutamate receptor signaling — the primary excitatory neurotransmission system underlying learning and memory. It acts as a positive allosteric modulator, enhancing receptor sensitivity without causing excitotoxicity. Enhanced glutamate signaling strengthens long-term potentiation (LTP), the synaptic basis of memory formation.
Boosting the attention messenger
- Noopept raises acetylcholine signalling by increasing the enzyme that makes it and sensitising its receptors.
- The source describes this as improving attention, working memory and cognitive processing speed.
▸Clinical wording
Cholinergic Enhancement
Noopept enhances acetylcholine signaling through increased choline acetyltransferase activity and nicotinic acetylcholine receptor sensitization. This cholinergic enhancement improves attention, working memory, and cognitive processing speed.
Several ways it shields nerve cells
- Noopept shows antioxidant activity, with less fat oxidation damage and more of a protective enzyme.
- It helps keep calcium balanced inside cells, preventing the overload that kills overexcited neurons.
- It shifts the balance of two proteins that decide whether a cell triggers its own death.
- The source frames these effects as relevant to neurodegenerative disease prevention, not as proven prevention.
▸Clinical wording
Neuroprotection
Noopept provides neuroprotection through multiple mechanisms: antioxidant activity (reduced lipid peroxidation, enhanced SOD), calcium homeostasis maintenance (preventing excitotoxic calcium overload), and anti-apoptotic signaling (increased Bcl-2/Bax ratio). These protective effects are relevant to neurodegenerative disease prevention.
Calming inflammation inside the brain
- Noopept reduces brain inflammation by suppressing activation of the brain's resident immune cells.
- It also lowers production of inflammatory signalling molecules within brain tissue.
- The source links this to both immediate cognitive effects and longer-term protection.
▸Clinical wording
Anti-Inflammatory CNS Effects
Noopept reduces neuroinflammation by suppressing microglial activation and pro-inflammatory cytokine production in the brain. This anti-neuroinflammatory effect contributes to both acute cognitive benefits and long-term neuroprotection.
Section 03
Biological Pathways
- BDNF/TrkB/CREB NeuroplasticityNoopept upregulates BDNF, activating TrkB→PLCγ/PI3K/Akt/MAPK→CREB phosphorylation→Arc, Zif268, BDNF gene transcription; this feedback loop sustains neuroplastic changes underlying memory and learning.
- AMPA/NMDA/CaMKII Synaptic PlasticityGlutamate receptor signaling→calcium influx→CaMKII activation→AMPA receptor phosphorylation and insertion→LTP strengthening; CaMKII is the switch converting synaptic activity into long-term memory traces.
- NGF/TrkA/Cholinergic PathwayNGF→TrkA→Ras/MAPK + PI3K/Akt→cholinergic neuron survival and choline acetyltransferase expression, maintaining the cholinergic system essential for attention and memory.
- HIF-1α Neuroprotective PathwayUnder hypoxic or stress conditions, Noopept stabilizes HIF-1α, driving expression of neuroprotective genes (erythropoietin, VEGF, glucose transporters), enhancing neuronal resilience to metabolic stress.
Section 04
Dosage Information
N-phenylacetyl-L-prolylglycine ethyl ester (dipeptide derivative)| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Oral — registered tablets | Russian label, memory and fatigue disorders | 10 mg tablets: 20 mg a day (morning, midday), up to 30 mg in three. After food, none after 18:00. 1.5–3 month courses, a month apart. | Approved after head injury, concussion or poor blood flow to the brain — damaged memory and attention, not a healthy adult's, which the label never mentions. |
| Oral — comparative trial | Open Russian trial, damage after injury or vessel disease | 53 patients: noopept 10 mg twice daily against piracetam 400 mg three times daily, for 56 days. | No placebo, everyone knew what they took, and piracetam is itself unapproved in the US. 56 days is also the longest follow-up, under the label course. |
| Oral / sublingual — self-administration | Sold as a nootropic supplement outside Russia | 10–30 mg a day — the label range restated. Powder under the tongue is improvised: nobody has measured how much is absorbed that way. | The FDA calls noopept an unapproved drug that cannot lawfully be sold as a supplement, so nothing checks the amount in a capsule: a claim, not a specification. |
Results
Syringe Fill Level (100u syringe)
Set positive values for: Recommended dose per kg.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Section 05
Protocols
- Protocol 01
Noopept Cognitive Enhancement
Fast-acting synthetic dipeptide nootropic for memory, learning, and neuroprotection.
- Focus
- Cognitive
- Level
- Beginner
- Duration
- 1.5–3 months
Section 06
Stability & Storage
Storing the product
Noopept is supplied as a white crystalline powder or as 10 mg tablets, kept at room temperature (15–25 °C) in a dry place. The commercial tablet form carries a shelf life of 3 years.
After opening
Once opened, containers are kept sealed and dry, since no separate post-opening timeframe is specified beyond the standard shelf life. The compound itself is chemically stable at physiological pH and resists acid hydrolysis, and for sublingual or intranasal use it can be dissolved in water or a PEG solution.
Section 07
Side Effects & Precautions
Clinical trials show a favorable safety profile, with adverse event rates comparable to placebo.
Effects Linked To Increased Brain Activity
- Mild headache is occasionally reported at higher doses; it may relate to enhanced cholinergic activity and can ease with an added choline source.
- Some users report mild restlessness or irritability, tied to enhanced glutamatergic and catecholaminergic activity; it is dose-dependent and eases at a lower dose.
- Taken too late in the day, Noopept's stimulating effect on cognitive circuits can interfere with sleep.
Digestive Effects
Occasional mild nausea or stomach discomfort has been reported; it is typically transient and resolves with continued use.
No Dependence or Withdrawal
Noopept does not produce tolerance, dependence, or a withdrawal syndrome in clinical experience. It can be started and stopped without gradually reducing the dose (tapering).
Allergic Reactions
Rare hypersensitivity (allergic) reactions have been reported. This reaction is associated with known sensitivity to pyrrolidone derivatives.
Section 08
Regulatory Status
Outside Russia its status diverges sharply: some regulators simply have not reviewed it, others restrict its sale, and at least one has banned it outright.
Russia
Approved nootropic medication
The State Register of Medicines lists Noopept as a registered pharmaceutical, sold over the counter in 10 mg tablets and marketed commercially since 2007.
FDA / United States
Not approved, but sold anyway
The FDA classifies omberacetam as an unapproved new drug under 21 U.S.C. §321(p)(1) and treats it as a piracetam analogue subject to import alerts, yet it remains widely sold as a dietary supplement.
Australia
Prescription-only under Schedule 4
The TGA lists omberacetam in Schedule 4 of the Poisons Standard, so buying, holding or supplying it in Australia without a doctor's prescription is unlawful.
United Kingdom
Not banned, but not licensed either
Noopept escapes the Psychoactive Substances Act 2016 because it does not act as a CNS stimulant or depressant. But it has no UK marketing authorisation, so selling or supplying it as a medicine remains unlawful — the MHRA has seized shipments on that basis.
WADA
Not on the prohibited list
Noopept does not appear on the WADA Prohibited List and is not a scheduled or controlled substance in most countries beyond the specific restrictions described above.
A single national approval does not make a substance approved everywhere, and being legal to buy in Russia does not make it legal to import elsewhere. Regulatory status differs by country and changes over time — check the current rules of your own jurisdiction before relying on any of this.
Section 09
Research Studies
- [1]Noopept stimulates the expression of NGF and BDNF in rat hippocampusOstrovskaya RU, Gudasheva TA, Zaplina AP, Vahitova JV, Salimgareeva MH, Jamidanov RS, et al. · Bulletin of Experimental Biology and Medicine · 2008
- [2]Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide NoopeptVakhitova YV, Sadovnikov SV, Borisevich SS, Ostrovskaya RU, Gudasheva TA, Seredenin SB · Acta Naturae · 2016
- [3]Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylationOstrovskaya RU, Vakhitova YV, Kuzmina USh, Salimgareeva MKh, Zainullina LF, Gudasheva TA, et al. · Journal of Biomedical Science · 2014
- [4]The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease modelOstrovskaya RU, Gruden MA, Bobkova NA, Sewell RD, Gudasheva TA, Samokhin AN, et al. · Journal of Psychopharmacology · 2007
- [5]Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke modelOstrovskaya RU, Romanova GA, Barskov IV, Shanina EV, Gudasheva TA, Victorov IV, et al. · Behavioural Pharmacology · 1999
- [6]Effects of nootropics on the EEG in conscious rats and their modification by glutamatergic inhibitorsVorobyov V, Kaptsov V, Kovalev G, Sengpiel F · Brain Research Bulletin · 2011
- [7]Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from ratKondratenko RV, Povarov IS, Kolbaev SN, Derevyagin VI, Ostrovskaya RU, Gudasheva TA · Neuroscience Letters · 2022
- [8]Noopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in RatsDüzova H, Nazıroğlu M, Çiğ B, Gürbüz P, Akatlı AN · Molecular Neurobiology · 2021
- [9]An experimental study of the anti-inflammatory action of noopept and its effect on the level of cytokinesAlekseeva SV, Kovalenko LP, Tallerova AV, Gudasheva TA, Durnev AD · Eksperimentalnaya i Klinicheskaya Farmakologiya · 2012
- [10]Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic originNeznamov GG, Teleshova ES · Neuroscience and Behavioral Physiology · 2009
Section 10
Frequently Asked Questions
In Russia it is an approved medication based on a comparative trial: 53 patients with cognitive impairment from brain injury or vascular disease were given noopept 10 mg twice daily against piracetam 400 mg three times daily for 56 days, with reported improvement in attention and memory. That trial had no placebo arm, everyone knew what they were taking, and it was run in people with diagnosed cognitive damage, not healthy adults.
Noopept (omberacetam) has been an over-the-counter approved medication in Russia since 2007. It is not approved by the FDA or European regulators, so in the US it is sold as a dietary supplement or research chemical under an ambiguous legal status rather than being formally banned; it is not on WADA's prohibited list and is not a controlled substance in most jurisdictions.
The Russian label for the 10 mg tablet specifies 20 mg a day split between morning and midday, rising to 30 mg in three doses, taken after food and none after 18:00, in courses of 1.5-3 months. That label covers people with memory or attention damage from head injury, concussion or poor cerebral blood flow - it does not address use in a healthy adult.
Its stimulating effect on cognitive circuits can interfere with sleep when the dose falls late in the day, which is why the label schedule stops by 18:00. This is listed among its reported side effects rather than measured in a dedicated sleep study.
Reported effects include mild headache (sometimes tied to increased cholinergic activity), irritability or restlessness, GI discomfort, and rare hypersensitivity reactions in people sensitive to pyrrolidone derivatives. Clinical trial adverse-event rates are described as comparable to placebo, and there is no reported dependence or withdrawal syndrome.
This is not among its documented effects. Its described mechanisms are neurotrophic (BDNF/NGF upregulation) and glutamatergic/cholinergic modulation, and no cited study measured euphoria or a subjective high as an outcome.
Noopept is described as roughly 1,000 times more potent than piracetam by weight, with an effective dose of 10-30 mg against piracetam's 2,400-4,800 mg. The only head-to-head data is the 56-day open-label trial in 53 patients with organic brain damage, where both drugs were associated with improvement and neither was compared against a placebo.